Clinical Trials
Active Biotech, Ipsen reach EUR10m milestone in Phase III study of tasquinimod
Active Biotech and Ipsen have announced the recruitment of 600 patients in randomized, placebo-controlled Phase III study of tasquinimod in metastatic castrate-resistant prostate cancer patients. The recruitment of half of target patient population triggered...
Clinical Trials
Peregrine reports results from phase II front-line lung cancer trial
Peregrine Pharmaceuticals has announced results from its randomized phase II trial, which is designed to determine overall response rate of carboplatin and paclitaxel with or without bavituximab in 86 patients with front-line, Stage IIIb and Stage IV non-small...
Clinical Trials
Circassia reports positive results from Phase II ragweed allergy therapy study
 Circassia, a specialty biopharmaceutical company, has announced positive results from Phase II clinical trial of ragweed allergy therapy.  According to the study, patients with more severe symptoms achieved a greater improvement following treatment with...
Clinical Trials
PhaseBio begins Phase I hypertension study with Vasomera
PhaseBio Pharmaceuticals, a biotechnology company, has initiated Phase I clinical study with its novel compound, Vasomera (PB1046), in patients with Stage 1 and 2 essential hypertension. The primary objective of the placebo-controlled study is...
Clinical Trials
TxCell reports positive immuno-monitoring results from Phase I/II Crohn’s disease study
TxCell SA, a biotechnology company, has announced positive immuno-monitoring results of the Phase I/II study in Crohn's disease with Ovasave. The open label, multicenter CATS1 study included 20 patients with severe chronic active Crohn's...
Clinical Trials
Galena initiates Phase III PRESENT trial for NeuVax
Galena Biopharma has initiated Phase III trial for NeuVax (E75 peptide plus GM-CSF) vaccine in HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence. The Prevention of Recurrence in...
Clinical Trials
Genta reports Tesetaxel Phase 2b trial data
Genta's Tesetaxel has demonstrated efficacy in the Phase 2b, confirmatory clinical trial, designed to evaluate the drug in patients with advanced gastric cancer. Tesetaxel is a novel, orally absorbed taxane that has been evaluated...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read